Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy

免疫疗法 MHC I级 癌症免疫疗法 免疫学 医学 佐剂 主要组织相容性复合体 癌症 免疫系统 肿瘤微环境 启动(农业) 癌症疫苗 细胞毒性T细胞 黑色素瘤 CD8型 抗原 临床试验 癌症研究 生物 计算生物学 生物信息学 免疫检查点 表位 精密医学 肽疫苗 个性化医疗 T细胞 肿瘤异质性 肿瘤科
作者
Xiyao Yu,Kai Fu
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:17: 1808146-1808146 被引量:8
标识
DOI:10.3389/fimmu.2026.1808146
摘要

Melanoma, owing to its high tumour mutational burden (TMB) and inherent immunogenicity, has emerged as a prime target for neoantigen-based customised cancer vaccines. Such vaccines may synergise with immune checkpoint inhibitors (ICIs) by harnessing patient-specific mutations to trigger targeted T-cell responses. This review systematically summarises and evaluates the clinical evidence and molecular mechanisms underlying customised neoantigen vaccines in melanoma, based on key clinical trial data. A central finding is that vaccine platform choice strongly influences, rather than rigidly determines, the dominant immunological pathway. Messenger RNA (mRNA) platforms generally favour endogenous antigen expression and MHC class I presentation, often eliciting robust CD8 + cytotoxic T-cell responses. By contrast, synthetic long peptide (SLP) platforms are typically processed as exogenous antigens and frequently engage MHC class II presentation, thereby promoting substantial CD4 + T-helper responses. However, this distinction is not absolute, because exogenous peptides can also be cross-presented on MHC class I by professional antigen-presenting cells, enabling CD8 + T-cell priming under appropriate conditions. Clinical data reflects this, with the mRNA vaccine mRNA-4157 (KEYNOTE-942) demonstrating a significant recurrence-free survival (RFS) benefit in the adjuvant setting. This efficacy, however, is contingent on the “hot” tumour microenvironment (TME) of melanoma; “cold” tumours like glioblastoma (GBM) and ovarian cancer (OvCa) present TME-specific barriers (e.g., the Blood-Brain Barrier, immune exclusion) that demand distinct, combination-based vaccine strategies. This review deconstructs this heterogeneity and defines the primary bottlenecks to broad clinical adoption: (1) the need to bridge the “validation gap” by correlating AI prediction accuracy with clinical outcomes; (2) the formidable economic and logistical barriers, including a clinically vulnerable 8–16 week manufacturing wait that poses psychological and clinical risks to patients; and (3) navigating adaptive regulatory pathways for “n-of-1” therapeutics. The field awaits the pivotal Phase III clinical trial of V940-001 (NCT05933577), whose timeline has been extended to 2029. This reflects the logistical and biological complexities inherent in developing personalised vaccines, highlighting challenges in both manufacturing and subject recruitment. These remain key obstacles impeding the widespread clinical application of such vaccines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿邪发布了新的文献求助10
刚刚
1秒前
1秒前
1秒前
1秒前
我是老大的应助被欢喜丝采纳,获得10
2秒前
2秒前
2秒前
2秒前
3秒前
Lucas的应助被威尔沐沐采纳,获得10
3秒前
4秒前
于林渤发布了新的文献求助10
4秒前
4秒前
新新新完成签到,获得积分10
5秒前
5秒前
6秒前
aaairplane发布了新的文献求助20
6秒前
6秒前
6秒前
6秒前
6秒前
fly完成签到,获得积分10
6秒前
哈哈哈发布了新的文献求助10
6秒前
d5hh的应助被diu采纳,获得30
6秒前
7秒前
周国煌发布了新的文献求助10
7秒前
新新新发布了新的文献求助10
7秒前
jinyue完成签到 ,获得积分10
8秒前
马鑫完成签到,获得积分10
8秒前
8秒前
8秒前
8秒前
8秒前
9秒前
9秒前
picOFFee完成签到,获得积分10
9秒前
9秒前
9秒前
Akim的应助被li采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188088
求助须知:如何正确求助?哪些是违规求助? 9575942
关于积分的说明 21844291
捐赠科研通 7785857
什么是DOI,文献DOI怎么找? 3435158
关于科研通互助平台的介绍 2559529
邀请新用户注册赠送积分活动 2482065